OSU James Cancer Hospital & Solove Research Institute  
 
Human Cancer Genetics Program
HomeAbout the ProgramResearchTraining OpportunitiesShared ResourcesFaculty & Staff
 
Home > Faculty & Staff > Faculty > Albert de la Chapelle



Administration
Faculty
Michael A. Caligiuri
Carlo M. Croce
Samir Acharya
Doreen Agnese
Dawn Allain
William E. Carson III
Albert de la Chapelle
Richard Fishel
Harold A. Fisk
Lawrence S. Kirschner
Michael A. Freitas
Gustavo Leone
Joanna Groden
Guido Marcucci
Denis C. Guttridge
Heather Hampel
Rebecca S. Nagy
Tatsuya Nakamura
Michael Ostrowski
Tim Hui-Ming Huang
Danilo Perrotti
Jeffrey D. Parvin, MD, PhD
Robert Pilarski
Kay Huebner
Yuri Pekarsky
Matthew D. Ringel
Amanda E. Toland
Stephan M. Tanner
Kevin Sweet
Leigha Senter
David Symer
Amy Sturm
Michael B. Weinstein
Judith Westman
Post Doctoral Staff
Staff
For Faculty and Staff
Albert de la Chapelle

Albert de la Chapelle, MD, PhD
Professor, Department of Molecular Virology, Immunology and Medical Genetics

804 Biomedical Research Tower

460 W 12th Ave

Columbus, OH 43210

Phone: (614) 688-4781
Fax: (614) 688-4772
albert.delachapelle@osumc.edu

Special Interests

Research in Dr. de la Chapelle’s laboratory focuses on the mapping, cloning, and characterization of high-penetrance genes for cancer predisposition.  Similar studies into low-penetrance genes, a relatively new concept, are also done.  When new genes are identified, studies are directed to determine the pathophysiological role of the proteins they encode, and the mechanisms by which mutations in the genes contribute to the cancer phenotype. Finally, there is an emphasis on translational aspects of the research, viz. the exploitation of laboratory discoveries towards new diagnostic and therapeutic procedures.  Diseases under study in the de la Chapelle laboratory include colorectal cancer, papillary thyroid cancer, and acute myeloid leukemia.   Colorectal cancer is highly heritable; nevertheless only a small fraction of all predisposing genes have been detected so far.  Very recently, the de la Chapelle laboratory discovered that a subtle reduction in the expression of one allele of the TGFBR1 gene is responsible for as many as 1 in 10 colorectal cancers.  The molecular basis of the reduced expression is being actively investigated. In papillary thyroid cancer predisposing germline mutations are sought by a variety of methods, including linkage, allelic association, and the determination of allelic differences in gene expression.  The role of non-coding RNA genes is emerging as a major cause of predisposition to papillary thyroid cancer.  One microRNA, 146a, has been implicated.  Carriers of a single nucleotide polymorphism in the pre-miR146a sequence have an elevated risk of thyroid cancer. It appears that heterozygotes for the polymorphism produce two abnormal mature miRs, whose target genes suggest the involvement of numerous downstream genes contributing to cancer development. In acute myeloid leukemia the group cloned a novel gene, BAALC for Brain and Acute Leukemia, Cytoplasmic that is expressed in early hematopoietic progenitor cells, and in a subset of the acute myeloid and lymphoid leukemias. Ongoing studies, including mouse modeling, aim at understanding the precise role of BAALC in leukemogenesis.  The working hypothesis is that BAALC is a marker of, or even a contributor to, blocked differentiation of these cells.   

Education

MD, University of Helsinki, FI, 1957
PhD, Human Genetics, Univ. of Helsinki, FI, 1962
Internship/Residency: University of Helsinki, FI, 1965
Subspecialty Training: University of Helsinki, FI, 1986
Postdoctoral Training: Biochemistry, Columbia University, 1968

Select Publications

Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomäki P, Chadwick RB, Kääriänen H, Percesepe A, Ahtola H, Härkönen N, Julkunen R, Kangas E, Ojala S, Tulikoura J, Valkamo E, Eskelinen M, Järvinen H, Mecklin JP, de la Chapelle A: Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. New Engl J Med 338:1481-1487, 1998

Tanner SM, Austin JL, Leone G, Rush LJ, Plass C, Heinonen K, Mrozek K, Sill H, Knuutila S, Kolitz JE, Archer KJ, Caligiuri MA, Bloomfield CD, de la Chapelle A: BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci USA 98:13901-13096, 2001

Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, Pellegata NS, de la Chapelle A: Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 98:15044-15049, 2001

Tanner SM, Aminoff M, Wright FA, Liyanarachchi S, Kuronen M, Saarinen A, Massika O, Mandel H, Broch H, de la Chapelle A: Amnionless, essential for mouse gastrulation, is mutated in recessive hereditary megaloblastic anemia. Nature Genet 33:426-429, 2003

Lynch HT, Coronel SM, Okimoto R, Hampel H, Sweet K, Lynch JF, Barrows A, Wijnen J, van der Klift H, Franken P, Wagner A, Fodde R, de la Chapelle A: A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. JAMA 291:718-724, 2004

Baldus CD, Liyanarachchi S, Mrozek K, Auer H, Tanner SM, Guimond M, Ruppert AS, Mohamed N, Davuluri RV, Caligiuri MA, Bloomfield CD, de la Chapelle A: Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21:amplification discloses overexpression of APP, ETS2 and ERG genes, PNAS 101:3915-3920, 2004

Tanner SM, Li Z, Perko JD, Oner C, Cetin M, Altay C, Yurtsever Z, David KL, Faivre L, Ismail EA, Grasbeck R, de la Chapelle A: Hereditary juvenile cobalamin deficiency caused by mutations in the intrinsic factor gene. Proc Natl Acad Sci U S A. 102:4130-4133, 2005

Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I, de la Chapelle A: Screening for the Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) New Engl J Med 352:1851-1860, 2005

He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu C-G, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A: The role of micro-RNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 102:19075-19080, 2005

Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I, LaJeunesse J, Nakagawa H, Westman JA, Prior TW, Clendenning M, Penzone P, Lombardi J, Dunn P, Cohn D, Copeland L, Eaton L, Fowler J, Lewandowski G, Vaccarello L, Bell J, Reid G, de la Chapelle A: Screening for Lynch Syndrome (HNPCC) among endometrial cancer patients. Cancer Res 66:7810-7817, 2006

Raval A, Tanner S, Byrd J, Angerman E, Perko J, Chen S-S, Grever M, Lucas D, Matkovic J, Lin T, Kipps T, Murry F, Weisenburger D, Sanger W, Lynch J, Watson P, Jansen M, Yoshinaga Y, Rosenquist R, de Jong P, Coggill P, Beck S, Lynch H, de la Chapelle A, Plass C: Down-regulation of death associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 129:879-890, 2007
 
Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA, Panescu J, Fix D, Lockman J, Lajeunesse J, Comeras I, de la Chapelle A.  Feasibility of Screening for Lynch Syndrome Among Patients With Colorectal Cancer.  J Clin Oncol. 2008 Sep 22. [Epub ahead of print]

Bonafé L, Hastbacka J, de la Chapelle A, Campos-Xavier AB, Chiesa C, Forlino A, Superti-Furga A, Rossi A.  A novel mutation in the sulphate transporter gene SLC26A2 (DTDST) specific to the Finnish population causes de la Chapelle dysplasia.  J Med Genet. 2008 Aug 15. [Epub ahead of print]

Valle L, Serena-Acedo T, Liyanarachchi S, Hampel H, Comeras I, Li Z, Zeng Q, Zhang HT, Pennison MJ, Sadim M, Pasche B, Tanner SM, de la Chapelle A. Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science. 2008 Sep 5;321(5894):1361-5. Epub 2008 Aug 14.





Arthur G. James Cancer Hospital and
Richard J. Solove Research Institute

1082 Biomedical Research Tower
460 West 12th Avenue
Columbus, OH 43210
Telephone: 614.292.3063
Contact Us
OSU James Cancer Hospital and Solove Research Institute